Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Condition:   Malignant Melanoma Stage III Interventions:   Drug: Domatinostat;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   The Netherlands Cancer Institute;   4SC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials